Atossa Genetics

Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. It offers ForeCYTE and ArgusCYTE diagnostic tests. The ForeCYTE Breast Health Test provides personalized information about the 10-year and lifetime risk of breast cancer for women between ages 18 and 65. The ArgusCYTE Breast Health Test offers information to help inform about breast cancer treatment options and to help monitor potential recurrence. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.

SEATTLE, Jan. 29, 2021 /PRNewswire/ -- A paper was published today by Dr. Steven Quay, M.D., PhD., CEO of Atossa Therapeutics, Inc. (NASDAQ: ATOS), entitled, "A Bayesian analysis concludes beyond a reasonable doubt that SARS-CoV-2 is not a natural zoonosis but instead is laboratory...

New Study By Dr. Steven Quay Concludes that SARS-CoV-2 Came from a Laboratory

SEATTLE, Jan. 25, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, announced that Dr. Steven C. Quay, President and CEO, will speak as a panelist at the 2021 Precision Medicine World Conference “21st Century Precision Medicine in the Age of COVID-19”

Atossa Therapeutics President and CEO Dr. Steven C. Quay to Speak at Precision Medicine World Conference, Spotlighting Anthony S.

The stock price of Atossa Therapeutics Inc (NASDAQ: ATOS) increased by over 11%. This is why it happened.

ATOS Stock Price Increases Over 11% Pre-Market: Why It Happened

HOUSTON, Jan. 8, 2021 /PRNewswire/ -- Dr. Steven Quay, M.D., PhD., head of two COVID-19 therapeutic programs at Atossa Therapeutics, Inc. (NASDAQ: ATOS ), recently shared his latest research and findings regarding the origins of COVID-19 and the manner in which it spread so quickly....

COVID-19 Origin and Spread Linked to PLA Hospital and Wuhan Metro System Line 2 by Physician-Scientist Dr. Steven Quay

SEATTLE, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (the “Company” or “Atossa”), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, announced today that it has entered into a securities purchase agreement with institutional investors to purchase $25.2 million of its shares of common stock and warrants in a registered direct offering priced at-the-market under Nasdaq rules. The combined purchase price for one share of common stock and .75 warrants to purchase one share of common stock is $1.055.

Atossa Therapeutics Announces Pricing of $25.2 Million Registered Direct Offering Priced At-The-Market

SEATTLE, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (the “Company” or “Atossa”), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, announced today that it has entered into a securities purchase agreement with institutional investors to purchase approximately $14.0 million of its common stock in a registered direct offering priced at-the-market under Nasdaq rules and warrants to purchase common stock in a concurrent private placement. The combined purchase price for one share of common stock and 0.75 warrants to purchase one share of common stock will be $1.00.

Atossa Therapeutics Announces Pricing of $14.0 Million Registered Direct Offering Priced At-The-Market

SEATTLE, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, announced today the pricing of an underwritten public offering with expected total gross proceeds of $20.0 million before deducting underwriting discounts, commissions and other offering expenses payable by the Company.

Atossa Therapeutics Announces Pricing of $20.0 Million Underwritten Public Offering

SEATTLE, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, today announced financial results for the third quarter ended September 30, 2020, and provided an update on recent company developments.

Atossa Therapeutics Announces Third Quarter 2020 Financial Results and Provides Corporate Update

SEATTLE, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, today announced blinded preliminary results from its Phase 1 clinical study using Atossa's proprietary drug candidate AT-301 administered by nasal spray. AT-301 was found to be safe and well tolerated in this study at two different dose levels in both single and multiple dose forms over 14 days. AT-301 is being developed for at home use for patients recently diagnosed with COVID-19. There are currently no FDA-approved therapies to treat COVID-19 at home.

Atossa Therapeutics Announces Preliminary Results from Phase 1 Clinical Study Showing Safety and Tolerability of AT-301 Nasal Spray Being Developed for COVID-19

SEATTLE, Oct. 28, 2020 /PRNewswire/ -- A paper published on Zenodo (DOI 10.5281/zenodo.4119263) by Dr. Steven Quay, M.D., PhD., head of two COVID-19 therapeutic programs at Atossa Therapeutics, Inc. (NASDAQ: ATOS), illuminates new scientific observations and conclusions documenting that...

New Research Points to the People's Liberation Army Hospital in Wuhan, China as the Origin for the Worldwide Coronavirus Pandemic

SEATTLE, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, today announced it has now completed enrollment in its Phase 1 clinical study using Atossa's proprietary drug candidate AT-301 administered by nasal spray.

Atossa Therapeutics Completes Enrollment of Phase 1 Clinical Study of AT-301 Nasal Spray Being Developed for the Coronavirus Causing COVID

In honor of October Breast Cancer Awareness Month, Atossa’s CEO Dr. Steven Quay, M.D., Ph.D. & CFO Kyle Guse will deliver a presentation titled “Atossa Therapeutics: Tackling our Greatest Health Challenges – COVID-19 and Breast cancer” In honor of October Breast Cancer Awareness Month, Atossa’s CEO Dr. Steven Quay, M.D., Ph.D. & CFO Kyle Guse will deliver a presentation titled “Atossa Therapeutics: Tackling our Greatest Health Challenges – COVID-19 and Breast cancer”

Registration Is Now Open For Atossa Therapeutics’ Tribe Public Webinar Presentation and Q&A Event On October 13, 2020

SEATTLE, Oct. 2, 2020 /PRNewswire/ -- Renowned physician-scientist Dr. Steven Quay, MD, PhD, and CEO of Atossa Therapeutics, Inc. (NASDAQ: ATOS) has provided 50 copies of his best-selling book, "Stay Safe: a Physician's Guide to Survive Coronavirus" to the White House following the news...

Physician-Scientist Dr. Steven Quay Provides Best-Selling Book, "Stay Safe: A Physician's Guide to Survive Coronavirus," to the White House Upon the News of COVID in the First Family

SEATTLE, Sept.  21, 2020  (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, today announces CEO Dr. Steven Quay and CFO Kyle Guse will be presenting at the Oppenheimer & Co. Fall Healthcare Life Sciences and MedTech Summit, which will be held virtually from September 21-23, 2020. The company is presenting at 9:10 AM ET on September 22nd.

Atossa Therapeutics To Present at the Oppenheimer & Co. Fall Healthcare Life Sciences and MedTech Summit on September 22, 2020

Safety Committee Allows Enrollment in First 14-Day, Multi-Dose Study Arm Safety Committee Allows Enrollment in First 14-Day, Multi-Dose Study Arm

Atossa Therapeutics Receives Second Positive Interim Safety Assessment in Clinical Study of AT-301 Nasal Spray Being Developed for the Coronavirus Causing COVID

SEATTLE, Sept.  01, 2020  (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, today announced a positive interim safety assessment from the first cohort of healthy participants in the Phase 1 clinical study using Atossa’s proprietary drug candidate AT-301 administered by nasal spray. This first group of 8 participants received a single dose of either AT-301A (placebo) or AT-301B (active drug). This blinded, positive assessment by the safety committee allows the study to now enroll the next cohort.

Atossa Therapeutics Announces Positive Interim Safety Assessment of First Group of Participants in Clinical Study of AT-301 Nasal Spray Being Developed for COVID-19

GSE Systems

TAT Technologies

Wireless Telecom Group

Yirendai Ltd. Sponsored

Volatility can be your best friend if you trade based on chart patterns. These penny stocks could be profitable in tumultuous times.

Penny Stocks to Buy Using Technical Analysis for September 2020

SEATTLE, Aug.  26, 2020  (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, today announces that Dr. Steven Quay, Atossa’s President and Chief Executive Officer, will give a virtual corporate presentation at the LD Micro 500 taking place online on Friday September 4, 2020 at 9:00 AM ET followed by a live Q&A session with registered investors and other conference attendees.

Atossa Therapeutics to Present at the LD Micro 500 Virtual Conference on September 4, 2020

SEATTLE, Aug.  17, 2020  (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, today announced that it has enrolled and dosed the first cohort of healthy participants in the Phase 1 clinical study using its proprietary drug candidate AT-301, being administered by nasal spray. This group of 8 participants received a single dose of either AT-301A (placebo) or AT-301B (active).

Atossa Therapeutics Announces  Enrollment and Dosing Completed in First Group of Healthy Participants in Clinical Study of AT-301 Nasal Spray Being Developed for Treatment of COVID-19

SEATTLE, Aug.  13, 2020  (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, today announced financial results for the second quarter ended June 30, 2020, and provided an update on recent company developments.  

Atossa Therapeutics Announces Second Quarter 2020 Financial Results and Provides Corporate Update

Enrollment Expected to Begin Within 30 days Enrollment Expected to Begin Within 30 days

Atossa Therapeutics Receives Approval to Open Clinical Study of AT-301 Nasal Spray  Being Developed to Treat COVID-19

Patient has taken Atossa’s Endoxifen for 18 months without side effects and without cancer recurrence Patient has taken Atossa’s Endoxifen for 18 months without side effects and without cancer recurrence

Atossa Therapeutics Announces Findings from FDA-Approved Expanded Access Treatment with Endoxifen

Atossa’s CEO, Dr. Steven Quay, M.D., Ph.D., will address recent progress with two COVID-19 treatment programs Atossa’s CEO, Dr. Steven Quay, M.D., Ph.D., will address recent progress with two COVID-19 treatment programs

Registration Is Now Open for Atossa Therapeutics’ Tribe Public Webinar Presentation and Q&A Event on July 30, 2020

SEATTLE, July  16, 2020  (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, announced that it has contracted with Avance Clinical Pty Ltd to conduct a clinical study of Atossa’s proprietary drug candidate AT-301, to be administered by nasal spray. Avance is a leading Australian clinical research organization and has successfully completed multiple clinical studies of Atossa’s proprietary Endoxifen.

Atossa Therapeutics Contracts for Clinical Study of AT-301 Nasal Spray, Atossa’s Second COVID-19 Therapeutic Development Program

Results Support Development of Proprietary AT-301 Nasal Spray for COVID-19 Patients Results Support Development of Proprietary AT-301 Nasal Spray for COVID-19 Patients

Atossa Therapeutics Announces Successful In Vitro Testing of Nasal Spray Formulation: AT-301 Inhibits SARS-CoV-2 Infectivity of VERO Cells in Laboratory Culture

News for Atossa Genetics Stock (ATOS)